Invivyd (IVVD) Stock Price, News & Analysis

Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $0.96 to $1.19
• 50-Day Range: $0.52 to $1.14
• 52-Week Range: $0.35 to $2.74
• Volume: 7.59 million shs
• Average Volume: 13.39 million shs
• Market Capitalization: $136.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.18
• Consensus Rating: Buy

Invivyd Stock Analysis - MarketRank™

Invivyd scored higher than 83% of companies evaluated by MarketBeat, and ranked 192nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

Invivyd has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Invivyd has a consensus price target of $3.18, representing about 179.2% upside from its current price of $1.14.

Amount of Analyst Coverage

Invivyd has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Invivyd are expected to grow in the coming year, from ($1.64) to $0.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Invivyd is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Invivyd is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Invivyd has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.97% of the float of Invivyd has been sold short.

Short Interest Ratio / Days to Cover

Invivyd has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Invivyd has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Invivyd does not currently pay a dividend.

Dividend Growth

Invivyd does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.97% of the float of Invivyd has been sold short.

Short Interest Ratio / Days to Cover

Invivyd has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Invivyd has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.88

News Sentiment

Invivyd has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Invivyd this week, compared to 4 articles on an average week.

Search Interest

27 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 238% compared to the previous 30 days.

MarketBeat Follows

8 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Invivyd insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,215.00 in company stock.

Percentage Held by Insiders

25.40% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IVVD Stock Analysis - Frequently Asked Questions

How have IVVD shares performed this year?

Invivyd's stock was trading at $0.4431 at the start of the year. Since then, IVVD stock has increased by 157.3% and is now trading at $1.14.

How were Invivyd's earnings last quarter?

Invivyd, Inc. (NASDAQ:IVVD) posted its earnings results on Thursday, August, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.08. The firm had revenue of $11.79 million for the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative trailing twelve-month return on equity of 177.89%.

Who are Invivyd's major shareholders?

Invivyd's top institutional shareholders include Maverick Capital Ltd. (8.53%), 683 Capital Management LLC (2.56%), Geode Capital Management LLC (0.53%) and Marshall Wace LLP (0.19%). Insiders that own company stock include Adimab, Llc, Jill Andersen, Timothy Edward Lee, Robert D Allen III, Julie Green and William E Duke.
View institutional ownership trends.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Invivyd own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IVVD
• CIK: 1832038
• Web: adagiotx.com
• Phone: 781-819-0080
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Invivyd: $3.18
• High Price Target: $5.00
• Low Price Target: $1.00
• Potential Upside/Downside: +179.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.93 million
• Net Margins: -238.33%
• Pretax Margin: -238.33%
• Return on Equity: -177.89%
• Return on Assets: -90.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $25.38 million
• Price / Sales: 5.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 120,140,000
• Free Float: 89,627,000
• Market Cap: $136.96 million
• Optionable: Optionable
• Beta: 0.55